Evolution of the Average Target: BioNTech SE

Evolution of the Target Price: BioNTech SE

Changes in Analyst Recommendations: BioNTech SE

47c3cad0091e8b.TY3MUaNe9029s_clqNERl5msUuouLLQORruDTGlvLx0.O9q-FpsqnSzMnqMQ3LBhxen4A6QfWsJ2a8zmJiwVZHsE6Ip86DuuefXCww~835b4a9e67ddf5af3317ef52229a7ca8
16/09 Berenberg Raises Price Target on BioNTech to $140 From $132, Keeps Buy Rating MT
16/09 BioNTech SE : UBS maintains a Buy rating ZD
16/09 BioNTech SE : Jefferies keeps its Buy rating ZD
16/09 BioNTech SE : Berenberg gives a Buy rating ZD
15/09 BioNTech SE : Jefferies maintains a Buy rating ZD
08/09 BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128 MT
04/09 BioNTech SE : Goldman Sachs gives a Buy rating ZD
28/08 Germany's DAX Index Extends Gains; BioNTech Tumbles After Scrapping Cancer Vaccine Trial MT
26/08 BioNTech SE : Deutsche Bank reiterates its Buy rating ZD
20/08 Cancer vaccines finally garner the spotlight Alphavalue
20/08 BioNTech SE : Jefferies keeps its Buy rating ZD
05/08 Berenberg Bank Adjusts BioNTech SE Price Target to $132 From $140, Maintains Buy Rating MT
05/08 BIONTECH : Berenberg reiterates its Buy rating ZD
05/08 BIONTECH : Gets a Buy rating from Jefferies ZD
05/08 BIONTECH : Bernstein sticks Neutral ZD
04/08 BioNTech: Q2 miss, followed by a sales guidance downgrade Alphavalue
04/08 Wall Street Bets on the Magnificent Seven Again Zonebourse
14/07 Where would AI lead Pharma in the long run? Alphavalue
08/07 Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating MT
01/06 BIONTECH : Buy rating from Jefferies ZD
27/05 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
27/05 BIONTECH : From Neutral to Buy by UBS ZD
27/05 UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117 MT
22/05 Bernstein Initiates Coverage on BioNTech With Market Perform Rating MT
12/05 Berenberg Still Confident on BioNTech Despite Lower Price Target Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+20.91%
+11.79%
+27.75%
+21.67%
+24.6%
+11.82%
+21.07%
+46.63%
+6.77%
+77.95%
Average +27.10%
Weighted average by Cap. +24.08%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
86.10EUR
Average target price
103.17EUR
Spread / Average Target
+19.83%
High Price Target
124.37EUR
Spread / Highest target
+44.46%
Low Price Target
65.19EUR
Spread / Lowest Target
-24.28%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. BNTX Stock
  4. Consensus BioNTech SE